Generex Oral-lyn (insulin buccal spray) / Generex, Dong Sung Pharma, Shreya Life Sci - LARVOL DELTA

Deformable Nanovesicle-Loaded Gel for Buccal Insulin Delivery. (PubMed, Pharmaceutics) - "Moreover, neither IPC-DNVs nor IPC-DNV-TSG induced significant mucosal irritation in rabbit tongue tissue sections. The study findings demonstrate a promising method for possible use as oral mucosal delivery of peptide drugs."

Journal

Celebrating A Century Of Insulin Discovery: A Critical Appraisal Of The Emerging Alternative Insulin Delivery Systems. (PubMed, Curr Drug Deliv) - "These efforts have not been without victory, as we have seen the emergence of pulmonary (Exubera and Afrezza) and buccal insulin delivery systems licenced for therapeutic use...However, at present, there are no clinical studies that have reported the efficacy of transdermal insulin administration With technological advancement, there is a potential to develop yet another insulin delivery system which would likely enter the markets. Although these novel delivery systems are welcome, however, emerging competing products should be welcome and appreciated."

Journal • Diabetes • Hypoglycemia • Immunology • Inflammation • Metabolic Disorders • Type 1 Diabetes Mellitus

Facilitated Buccal Insulin Delivery via Hydrophobic Ion-Pairing Approach: In vitro and ex vivo Evaluation. (PubMed, Int J Nanomedicine) - "The increase in fluorescence intensity was observed in the order of C1 > C2 > insulin solution. In this study, we highlighted the efficacy of potential nanocarriers in addressing the daunting issues associated with the invasive administration of insulin and indicated a promising strategy for the buccal administration and delivery of this life-saving peptide hormone."

Journal • Preclinical

Cell-Penetrating Peptide Enhanced Insulin Buccal Absorption. (PubMed, Int J Pharm) - "INS-PEG-LMWP's relative pharmacological bioavailability was high and its relative bioavailability was up to 26.86%, demonstrating no visible mucosal irritation. Cell-penetrating peptides are likely to become a reliable and safe tool for overcoming insulin's low permeability through the epithelial multilayers, the major barrier to buccal delivery."

Journal

In honor of Prof. Stacey Bent: Self-assembly across substrates (ACS-Sp 2018) - "These design elements, in turn, enable controlled chemical patterning from the sub-nanometer to the centimeter scales. We simultaneously develop metrology tools for these methods to give unprecedented insight on the structures, function, and properties of these assemblies."

Biosimilar

Generex's Glucose RapidSpray now available at boots UK retail chain stores (Benzinga) - Glucose RapidSpray is a proprietary, innovative alternative for people who require or want additional glucose

Diabetes

In situ binding recognition of phospholipid-guanidinium interactions at the air/water interface (ACS-Sp 2018) - "Molecular binding interactions were determined using a combination of techniques including Brewster angle microscopy (BAM) to study the morphology of this system, and IRRAS to elucidate the binding motif. This study demonstrates the utility of studying the mechanistic binding processes of organized monolayers which will be used as a basis to design new biologically-inspired synthetic receptors for phosphate capture."

Biosimilar

Generex Biotechnology Corporation (GNBT) company brief - The company announced the preliminary outcomes and trends from Generex Oral-lyn’s ongoing P3 clinical trial; President and CEO of Generex, was pleased that the key characteristics monitored throughout insulin treatments are trending favorably;

Generex provides further information for March 30 press conference & investor call to discuss management's strategic development plan for future growth (PRNewswire) - Generex provided further information regarding the company's press conference and investor call scheduled for Mar 30 ’11; Management will discuss its plan to advance the development of Oral-lyn and the Antigen Express AE37 immunotherapeutic cancer vaccine platform

Diabetes

In-depth evaluation of next generation protein A stationary phases (ACS-Sp 2018) - No abstract available.

Biosimilar

In situ electrodeposition of RGO for detection of trace metals (ACS-Sp 2018) - "The in situ deposition of RGO enhances the reduction of metal ions on the electrode surface, which improves the sensitivity of the sensor compared to RGO film electrodes. Besides, the morphology of the electrodeposited RGO on the electrode was studied using scanning electron microscopy, and Cd was also used as target analyte."

Biosimilar • Ophthalmology

In-free thin-film solar cells: Cu2ZnSn(S,Se)4 films generated from a single molecular precursor solution (ACS-Sp 2018) - No abstract available.

Preclinical • Biosimilar

Generex provides update on Generex Oral-lyn™ conference call (PRNewswire) - "...provided an update in respect of the previously announced conference call on the Company's proprietary Generex Oral-lyn™ buccal insulin spray program...focus on recent developments, the planned Generex Oral-lyn™ formulation and process improvements, and the go-forward strategy for the expansion of the Generex Diabetes Program..."

Clinical • Diabetes

In-situ scattering techniques to study synthesis and crystallization processes of colloidal nanocrystals (ACS-Sp 2018) - "Furthermore, the discovery of crystallization processes occurring during the synthesis process will be discussed, with the opportunity to engineer not only the structure of individual nanocrystals, but also to extend this control to self-assembled materials such as superlattices. This increased knowledge, corroborated by thermodynamic models, is utilized to tune and control the size and composition of colloidal nanocrystals, which are important parameters in their applications in many areas, for example in catalysis."

Biosimilar

Generex to participate in Canadian Diabetes Association Conference (PRNewswire) -

Generex participated in the 13th Annual Canadian Diabetes Association (CDA), Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference and Annual Meetings on Oct 20-23 ’10

 

In situ investigation of methane dry reforming on M-CeO2 {M= Co, Ni, Cu} catalysts: Metal-support interactions and the activation of C-H bonds at room temperature (ACS-Sp 2018) - "At 700 K, under methane dry reforming conditions, CO2 dissociates on the oxide surface and a catalytic cycle is established without coke deposition. A significant part of the CHx formed on the Co0/CeO2-x catalyst recombines to yield ethane or ethylene."

Biosimilar

Generex Biotechnology Corporation (GNBT) company brief (Beaconequity) - The company announced the preliminary outcomes and trends from Generex Oral-lyn’s ongoing P3 clinical trial; President and CEO of Generex, was pleased that the key characteristics monitored throughout insulin treatments are trending favorably;

In search for metal-free catalytic motifs for solar fuels (ACS-Sp 2018) - "Our preliminary kinetic studies using ultrafast pump-probe spectroscopy on a series of NAD+ analogs suggest that the hole injection into the inorganic semiconductor (GaP) occurs efficiently with dyes that have sufficiently long excited-state lifetimes. In addition, the hydricities of a series of NADH analogs were evaluated, showing that some of the model compounds investigated are excellent hydride donors."

Biosimilar

In-situ neutron scattering studies of hydride conducting alkaline earth-metal hydrides (ACS-Sp 2018) - "We used quasi-elastic neutron scattering (QENS) and powder neutron diffraction (PND) studies to elucidate the probable diffusion pathway for hydride ions in the BaH2 lattice. Furthermore, studies using QENS and PND were used to elucidate the effect of the introduction of nitrogen into the crystal lattice on ion conductivity."

Biosimilar

Speaker (IDF 2019) - "Newer injectables like glargine 300 U/ml and degludec are ultra long-acting insulins which reduced the number of pricks and had good glycemic control with less hypoglycemia...Exubera was first rapid-acting inhaled insulin in the market, but it was withdrawn in 2007 due to fewer acceptances by physicians and patients. Newer inhaled insulin Afrezza based on a technosphere platform contains recombinant human insulin administered via a small thumb-sized device introduced in 2014 with modification in the size of the device...Other different ways of administration of insulin which can bypass hepatic first-pass metabolism are in a different phase of trial like buccal insulin, nasal insulin, ocular insulin; rectal insulin (bypasses the more proximal areas that are actively involved indigestion)...The preclinical study result has shown that SOMA has released the same plasma level of insulin compare to subcutaneous millipost administration. Learning Objectives History and..."

A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade. (PubMed, Drug Discov Today) - "To increase patient compliance, products are slowly reaching the market that are more patient friendly, such as the insulin patch-pump systems, including Omnipod and V-Go, but also the inhaled-insulin Afrezza and the buccal insulin Oral-lyn™. In this review, we outline the history of insulin, the various options that are currently available in practice for insulin delivery, and the non-invasive delivery systems that have entered the different stages of clinical trials over the past decade."

Clinical • Journal • Review